250 Participants Needed

MRI-Guided Radiotherapy for Cancer

NU
Overseen ByNawaid Usmani, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: AHS Cancer Control Alberta
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

Cancers are often treated with external beam radiotherapy. Current radiotherapy treatments are performed using computed tomography (also known as CT) scans which may not always clearly identify the cancer. In some instances, magnetic resonance imaging (MRI) may be able to better identify cancers. Therefore, efforts are currently underway to use the MRI scans to improve radiotherapy treatments or eventually even use radiotherapy equipment that only uses MRI scans to guide treatments. This new technology that will only use MRI scans to guide treatments is called the Linac-MR (linear accelerator with an MRI). The purpose of this pilot phase of the study is to test whether the Alberta linac-MR P3 system at the Cross Cancer Institute can acquire high quality MR images safely. It will allow the researchers to develop the best collection of MR images possible with this new machine, in order to allow them to visualize tumors for future patients that are treated on this machine.

Research Team

NU

Nawaid Usmani, MD

Principal Investigator

Cross Cancer Institute, Alberta Health Services

Eligibility Criteria

This trial is for adults over 18 who are fit for high dose radiation therapy as determined by their oncologist. It's not suitable for those unable to lie flat and still during scans, cannot consent, or have conditions that make MRI use unsafe.

Inclusion Criteria

My doctor thinks I can handle a strong radiation treatment.

Exclusion Criteria

I am unable to understand and give consent for treatment.
I cannot stay still or lie flat for long periods.
You cannot have an MRI for medical reasons.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

MR Imaging

Participants undergo a single MR imaging session on the Alberta linac-MR P3 system

1 day
1 visit (in-person)

Optional Sub-study

Participants may undergo additional MR imaging sessions to assess inter-fraction motion

Up to 5 weeks
5 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after imaging sessions

4 weeks

Treatment Details

Interventions

  • MR scan with the Alberta linac-MR P3 system
Trial Overview The study tests the Alberta linac-MR P3 system's ability to safely acquire high-quality MR images at the Cross Cancer Institute. The goal is to improve tumor visualization in radiotherapy using only MRI guidance.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: MR Imaging on the Alberta linac-MR P3 systemExperimental Treatment1 Intervention
All participants will undergo a single MR imaging session (30-40 minutes) on the Alberta linac-MR P3 system.

Find a Clinic Near You

Who Is Running the Clinical Trial?

AHS Cancer Control Alberta

Lead Sponsor

Trials
188
Recruited
26,900+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security